A I Veldkamp
Overview
Explore the profile of A I Veldkamp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
242
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Graaf P, De Boer N, Wong D, Karner S, Jharap B, Hooymans P, et al.
Br J Pharmacol
. 2010 Jul;
160(5):1083-91.
PMID: 20590602
Background And Purpose: 5-aminosalicylate (5-ASA) raises levels of 6-thioguanine nucleotides (6-TGN), the active metabolites of thiopurines such as azathioprine (AZA). Changes in levels of each individual TGN - 6-thioguanosine mono-,...
2.
de Graaf P, Vos R, de Boer N, Sinjewel A, Jharap B, Mulder C, et al.
J Chromatogr B Analyt Technol Biomed Life Sci
. 2010 Apr;
878(19):1437-42.
PMID: 20399153
Background: Monitoring of thiopurine metabolites 6-thioguanine nucleotides (6-TGN) and 6-methylmercaptopurine (6-MMP) is used to assess compliance and explain adverse reactions in IBD-patients. Correlations between dosage, metabolite concentrations and therapeutic efficacy...
3.
Veldkamp A, van Heeswijk R, Mulder J, Meenhorst P, Hoetelmans R, Lange J, et al.
Ther Drug Monit
. 2002 Jan;
23(6):606-11.
PMID: 11802091
The objective of this study was to develop and validate a limited sampling strategy (LSS) that allows accurate and precise estimation of the area under the plasma concentration versus time...
4.
Veldkamp A, Meenhorst P, Mulder J, Beijnen J
J Acquir Immune Defic Syndr
. 2001 Dec;
28(5):495-6.
PMID: 11744840
No abstract available.
5.
Veldkamp A, van Heeswijk R, Mulder J, Meenhorst P, Schreij G, van der Geest S, et al.
J Acquir Immune Defic Syndr
. 2001 Jul;
27(4):344-9.
PMID: 11468422
Objective: To compare the steady state plasma pharmacokinetics of 1000 mg of saquinavir (SQV) in a soft-gel capsule (SGC) formulation in combination with 100 mg of ritonavir (RTV) (capsules) in...
6.
Veldkamp A, Weverling G, Lange J, Montaner J, Reiss P, Cooper D, et al.
AIDS
. 2001 Jun;
15(9):1089-95.
PMID: 11416710
Objective: To explore relationships between exposure to nevirapine and the virological response in HIV-1-infected individuals participating in the INCAS trial. Methods: The elimination rate constant of plasma HIV-1 RNA (k)...
7.
Veldkamp A, Harris M, Montaner J, Moyle G, Gazzard B, Youle M, et al.
J Infect Dis
. 2001 Jun;
184(1):37-42.
PMID: 11398107
The steady-state pharmacokinetics of efavirenz and nevirapine, when used in combination to treat human immunodeficiency virus type 1 (HIV-1)-infected subjects, were investigated. HIV-1-infected persons who had used efavirenz (600 mg...
8.
van Heeswijk R, Veldkamp A, Mulder J, Meenhorst P, Beijnen J, Lange J, et al.
Ther Drug Monit
. 2001 May;
23(3):255-8.
PMID: 11360034
The objective of this study was to evaluate the applicability of saliva as an alternative body fluid for therapeutic drug monitoring of nevirapine. The pharmacokinetics of nevirapine in plasma and...
9.
van Heeswijk R, Veldkamp A, Mulder J, Meenhorst P, Wit F, Reiss P, et al.
J Acquir Immune Defic Syndr
. 2000 Nov;
25(1):93-5.
PMID: 11064511
No abstract available.
10.
van Heeswijk R, Veldkamp A, Mulder J, Meenhorst P, Lange J, Beijnen J, et al.
AIDS
. 2000 Jul;
14(9):F103-10.
PMID: 10894270
Objective: To investigate the steady-state pharmacokinetics of a once-daily dosing regimen of saquinavir soft gelatin capsules in combination with a low dose of ritonavir in HIV-1-infected individuals. Design: Open-label, multi-dose,...